Although BRAF V600E, which is the most common BRAF mutation in many cancer types, is a poor prognostic factor in metastatic cancer [41], it is nevertheless a promising target for personalized medicine, and the combination of specific BRAF V600E inhibitors with other MAPK/PI3K pathway inhibitors has been shown to be more effective for treating metastatic CRC [42]. This evidence concerns the gene BRAF and cancer.